You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Details for New Drug Application (NDA): 212024

✉ Email this page to a colleague

« Back to Dashboard

NDA 212024 describes LEVORPHANOL TARTRATE, which is a drug marketed by Acertis Pharms, Hikma, Novitium Pharma, Specgx Llc, and Sun Pharm Inds Inc, and is included in five NDAs. It is available from seven suppliers. Additional details are available on the LEVORPHANOL TARTRATE profile page.

The generic ingredient in LEVORPHANOL TARTRATE is levorphanol tartrate. There are six drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the levorphanol tartrate profile page.

Summary for 212024

Tradename:	LEVORPHANOL TARTRATE
Applicant:	Specgx Llc
Ingredient:	levorphanol tartrate
Patents:	0

Pharmacology for NDA: 212024

Mechanism of Action	Full Opioid Agonists

Medical Subject Heading (MeSH) Categories for 212024

Analgesics, Opioid
Narcotics

Suppliers and Packaging for NDA: 212024

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
LEVORPHANOL TARTRATE	levorphanol tartrate	TABLET;ORAL	212024	ANDA	SpecGx LLC	0406-2224	0406-2224-01	100 TABLET in 1 BOTTLE, PLASTIC (0406-2224-01)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	2MG
Approval Date:	Dec 13, 2019	TE:	AB	RLD:	No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.